Skip to contentS
Spyre Therapeutics, Inc.
S
SYRESpyre Therapeutics, Inc. Q2 2025 · 10-Q
Revenue—
Net Income-$36.72M-$36.72MN/M vs Q2 2024 EPS, diluted—
Operating Income-$41,935,000N/M Operating Cash Flowderived-$46,563,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d after period end